ADMP
Adamis Pharmaceuticals Corporation
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 11-09-2018 | 08-10-2018 | 05-10-2018 | 03-15-2018 | 08-14-2017 | 05-12-2017 | |
|---|---|---|---|---|---|---|
| Actual EPS | -0.21 | -0.29 | -0.23 | -0.24 | -0.19 | -0.26 |
| Consensus EPS | -0.15 | -0.17 | -0.17 | -0.21 | ||
| Estimated EPS | -0.15 | -0.17 | -0.17 | -0.21 | ||
| Number of Estimates | 3 | 3 | 3 | 1 | ||
| EPS Surprise | -$0.06 | -$0.12 | -$0.06 | -$0.05 |
Stats
Summary
Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company that develops & commercializes products in the therapeutic areas of respiratory disease & allergy. Its products include Epinephrine Injection PFS syringe, APC-1000, APC-2000, & APC-5000.
Market Cap: 135 Million
Primary Exchange: NASDAQ Capital Market
Website: http://www.adamispharmaceuticals.com
Shares Outstanding: 33.4 Million
Float: 25.2 Million
Dividend: 0.0 (0.0%)
Beta: 0.242532
Sector: Healthcare
Industry: Drug Manufacturers
Short Interest (Jan 12, 2018): 2.63 Million
Ethical Flags
Longest drawdown: 1470 trading days
From: 2013-02-12 To: 2018-12-07
Lowest Point:
ADMP And Sandoz Announce Plans For SYMJEPI Launch
via: SeekingAlpha at 2018-12-07 13:24:09:000
Sources Investors finally received updates from Adamis ( ADMP ) and Sandoz about the planned launch of SYMJEPI. The Adamis press release was short, but provided some insight on the companys recent actions to support the launch. According to the press release, Manufact… read more...
ADMP And Sandoz Announce Plans For SYMJEPI Launch
via: SeekingAlpha at 2018-12-07 13:24:09:000
Sources Investors finally received updates from Adamis ( ADMP ) and Sandoz about the planned launch of SYMJEPI. The Adamis press release was short, but provided some insight on the companys recent actions to support the launch. According to the press release, Manufact… read more...
ADMP And Sandoz Announce Plans For SYMJEPI Launch
via: SeekingAlpha at 2018-12-07 13:24:09:000
Sources Investors finally received updates from Adamis ( ADMP ) and Sandoz about the planned launch of SYMJEPI. The Adamis press release was short, but provided some insight on the companys recent actions to support the launch. According to the press release, Manufact… read more...
ADMP And Sandoz Announce Plans For SYMJEPI Launch
via: SeekingAlpha at 2018-12-07 13:24:09:000
Sources Investors finally received updates from Adamis ( ADMP ) and Sandoz about the planned launch of SYMJEPI. The Adamis press release was short, but provided some insight on the companys recent actions to support the launch. According to the press release, Manufact… read more...
Time To Get Onboard Adamis?
via: SeekingAlpha at 2018-11-15 09:40:13:000
Sources Company Overview Adamis (ADMP) is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas. The company's flagship product SYMJEPI is a pre-filled syringe ((PFS)) device containing 0.3mg or 0.15mg dose of … read more...
Time To Get Onboard Adamis?
via: SeekingAlpha at 2018-11-15 09:40:13:000
Sources Company Overview Adamis (ADMP) is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas. The company's flagship product SYMJEPI is a pre-filled syringe ((PFS)) device containing 0.3mg or 0.15mg dose of … read more...
Time To Get Onboard Adamis?
via: SeekingAlpha at 2018-11-15 09:40:13:000
Sources Company Overview Adamis (ADMP) is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas. The company's flagship product SYMJEPI is a pre-filled syringe ((PFS)) device containing 0.3mg or 0.15mg dose of … read more...
Adamis: Here We Go Again!
via: SeekingAlpha at 2018-11-13 16:39:06:000
Source: Flickr Adamis ( ADMP ) must be one of the most frustrating stocks to own; time and again with good news ADMP sees a stock price rise followed a sharp fall. The company has approval for Symjepi, the epinephrine syringe, that will compete against Mylan's ( MYL ) EpiPen. The good … read more...
Adamis: Here We Go Again!
via: SeekingAlpha at 2018-11-13 16:39:06:000
Source: Flickr Adamis ( ADMP ) must be one of the most frustrating stocks to own; time and again with good news ADMP sees a stock price rise followed a sharp fall. The company has approval for Symjepi, the epinephrine syringe, that will compete against Mylan's ( MYL ) EpiPen. The good … read more...
PCG, EIX, BTI, SAP among premarket losers
via: SeekingAlpha at 2018-11-12 09:19:05:000
Lumentum Holdings (NASDAQ: LITE ) -26% after Q2 guidance . More news on: Lumentum Holdings Inc., GNC Holdings, Inc., PG&E Corporation, Stocks on the move, , Top stock market news, Read more … read more...
JPMorgan downgrades Infinity Pharma to Underweight in premarket analyst action
via: SeekingAlpha at 2018-11-12 08:11:04:000
Adamis Pharmaceuticals (NASDAQ: ADMP ) downgraded to Neutral with a $2.50 (11% downside risk) price target at B. Riley FBR citing the slow ramp of Symjepi and soft performance of its compounding business. More news on: Adamis Pharmaceuticals Corp., Nobilis Health Corp., Infinity Pharmaceut… read more...
Adamis Pharmaceuticals misses on revenue
via: SeekingAlpha at 2018-11-09 16:55:31:000
Adamis Pharmaceuticals (NASDAQ: ADMP ): Q3 Revenue of $3.8M (+11.8% Y/Y) misses by $1.43M . Cash and cash equivalents of $32.0M. Press Release More news on: Adamis Pharmaceuticals Corp., Earnings news and commentary, Healthcare stocks news, , read more...
Adamis Pharmaceuticals misses on revenue
via: SeekingAlpha at 2018-11-09 16:55:31:000
Adamis Pharmaceuticals (NASDAQ: ADMP ): Q3 Revenue of $3.8M (+11.8% Y/Y) misses by $1.43M . Cash and cash equivalents of $32.0M. Press Release More news on: Adamis Pharmaceuticals Corp., Earnings news and commentary, Healthcare stocks news, , read more...
Adamis Pharmaceuticals misses on revenue
via: SeekingAlpha at 2018-11-09 16:55:31:000
Adamis Pharmaceuticals (NASDAQ: ADMP ): Q3 Revenue of $3.8M (+11.8% Y/Y) misses by $1.43M . Cash and cash equivalents of $32.0M. Press Release More news on: Adamis Pharmaceuticals Corp., Earnings news and commentary, Healthcare stocks news, , read more...
FDA to hold Ad Com meeting aimed at increasing access to opioid overdose med naloxone
via: SeekingAlpha at 2018-10-23 13:07:55:000
The FDA announces a two-day advisory committee, to be held in December, to solicit input and advice on ways to increase access to opioid overdose medication naloxone. More news on: Emergent BioSolutions Inc., Adamis Pharmaceuticals Corp., Opiant Pharmaceuticals, Inc., Healthcare stocks n… read more...
FDA to hold Ad Com meeting aimed at increasing access to opioid overdose med naloxone
via: SeekingAlpha at 2018-10-23 13:07:55:000
The FDA announces a two-day advisory committee, to be held in December, to solicit input and advice on ways to increase access to opioid overdose medication naloxone. More news on: Emergent BioSolutions Inc., Adamis Pharmaceuticals Corp., Opiant Pharmaceuticals, Inc., Healthcare stocks n… read more...
FDA to hold Ad Com meeting aimed at increasing access to opioid overdose med naloxone
via: SeekingAlpha at 2018-10-23 13:07:55:000
The FDA announces a two-day advisory committee, to be held in December, to solicit input and advice on ways to increase access to opioid overdose medication naloxone. More news on: Emergent BioSolutions Inc., Adamis Pharmaceuticals Corp., Opiant Pharmaceuticals, Inc., Healthcare stocks n… read more...
Adamis And Novartis: Gunning For Mylan's EpiPen
via: SeekingAlpha at 2018-10-04 07:30:00:000
Product Pipeline Adamis' ( ADMP ) lead product is the Symjepi pre-filled syringe injector that contains epinephrine for its use in the treatment of acute allergic reactions, including anaphylaxis, a serious life-threatening allergic reaction. Adamis offers a high dose 0.30mg variant for pa… read more...
Adamis And Novartis: Gunning For Mylan's EpiPen
via: SeekingAlpha at 2018-10-04 07:30:00:000
Product Pipeline Adamis' ( ADMP ) lead product is the Symjepi pre-filled syringe injector that contains epinephrine for its use in the treatment of acute allergic reactions, including anaphylaxis, a serious life-threatening allergic reaction. Adamis offers a high dose 0.30mg variant for pa… read more...
Adamis And Novartis: Gunning For Mylan's EpiPen
via: SeekingAlpha at 2018-10-04 07:30:00:000
Product Pipeline Adamis' ( ADMP ) lead product is the Symjepi pre-filled syringe injector that contains epinephrine for its use in the treatment of acute allergic reactions, including anaphylaxis, a serious life-threatening allergic reaction. Adamis offers a high dose 0.30mg variant for pa… read more...
Adamis Pharmaceuticals: Where Do We Go From Here?
via: SeekingAlpha at 2018-10-01 00:01:02:000
For investors in Adamis Pharmaceuticals (ADMP), the wait is finally over. On Thursday, Adamis obtained approval for its low-dose Epinephrine medication, Symjepi. The company previously had approval for the 0.30mg version of Symjepi, and the FDA approval of Symjepi for a 0.15mg dose for pedia… read more...
Adamis Pharmaceuticals: Where Do We Go From Here?
via: SeekingAlpha at 2018-10-01 00:01:02:000
For investors in Adamis Pharmaceuticals (ADMP), the wait is finally over. On Thursday, Adamis obtained approval for its low-dose Epinephrine medication, Symjepi. The company previously had approval for the 0.30mg version of Symjepi, and the FDA approval of Symjepi for a 0.15mg dose for pedia… read more...
Adamis Pharmaceuticals: Where Do We Go From Here?
via: SeekingAlpha at 2018-10-01 00:01:02:000
For investors in Adamis Pharmaceuticals (ADMP), the wait is finally over. On Thursday, Adamis obtained approval for its low-dose Epinephrine medication, Symjepi. The company previously had approval for the 0.30mg version of Symjepi, and the FDA approval of Symjepi for a 0.15mg dose for pedia… read more...
Midday Gainers / Losers (09/28/2018)
via: SeekingAlpha at 2018-09-28 12:40:43:000
Gainers: SYN +207% . IGC +36% . NBEV +31% . AYTU +23% . ZN +21% . CCXI +17% . IMMP +14% . SPNS +14% . PRSS +13% . AC +12% . More news on: Synthetic Biologics, Inc., India Globalization Capital, Inc, New Age Beverages Corporation, Stocks on the move, , Top s… read more...
Midday Gainers / Losers (09/28/2018)
via: SeekingAlpha at 2018-09-28 12:40:43:000
Gainers: SYN +207% . IGC +36% . NBEV +31% . AYTU +23% . ZN +21% . CCXI +17% . IMMP +14% . SPNS +14% . PRSS +13% . AC +12% . More news on: Synthetic Biologics, Inc., India Globalization Capital, Inc, New Age Beverages Corporation, Stocks on the move, , Top s… read more...
Midday Gainers / Losers (09/28/2018)
via: SeekingAlpha at 2018-09-28 12:40:43:000
Gainers: SYN +207% . IGC +36% . NBEV +31% . AYTU +23% . ZN +21% . CCXI +17% . IMMP +14% . SPNS +14% . PRSS +13% . AC +12% . More news on: Synthetic Biologics, Inc., India Globalization Capital, Inc, New Age Beverages Corporation, Stocks on the move, , Top s… read more...
FDA OKs Adamis Pharma's low-dose Symjepi
via: SeekingAlpha at 2018-09-27 16:18:11:000
The FDA approves Adamis Pharmaceuticals' (NASDAQ: ADMP ) lower-dose version (0.15 mg) of emergency allergic reaction med Symjepi (epinephrine) for pediatric use. More news on: Adamis Pharmaceuticals Corp., Novartis AG, Healthcare stocks news, Stocks on the move, Read more … read more...
Catalyst Watch: Adamis Faces A Big FDA Decision This Week On Symjepi Jr.
via: SeekingAlpha at 2018-09-25 12:37:52:000
Adamis Pharmaceuticals ( ADMP ) faces its next big FDA hurdle this week. September 27 th is the PDUFA deadline for Symjepi Jr., the low dose variant of the companys Symjepi product, a prefilled syringe injector for delivering epinephrine to patients. All approval decisions carry ris… read more...
Catalyst Watch: Adamis Faces A Big FDA Decision This Week On Symjepi Jr.
via: SeekingAlpha at 2018-09-25 12:37:52:000
Adamis Pharmaceuticals ( ADMP ) faces its next big FDA hurdle this week. September 27 th is the PDUFA deadline for Symjepi Jr., the low dose variant of the companys Symjepi product, a prefilled syringe injector for delivering epinephrine to patients. All approval decisions carry ris… read more...
Premarket Gainers as of 9:05 am (09/25/2018)
via: SeekingAlpha at 2018-09-25 09:19:16:000
JONE +47% . More news on: Jones Energy, Inc., Applied DNA Sciences, Inc., Clean Diesel Technologies, Inc., Stocks on the move, , Top stock market news, Read more … read more...
Premarket Gainers as of 9:05 am (09/25/2018)
via: SeekingAlpha at 2018-09-25 09:19:16:000
JONE +47% . More news on: Jones Energy, Inc., Applied DNA Sciences, Inc., Clean Diesel Technologies, Inc., Stocks on the move, , Top stock market news, Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-09-21 11:11:59:000
Noteworthy events during the week of September 23 - 29 for healthcare investors. More news on: Loxo Oncology, CHECKPOINT THERAPEUTICS, Iovance Biotherapeutics, Inc., Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-09-21 11:11:59:000
Noteworthy events during the week of September 23 - 29 for healthcare investors. More news on: Loxo Oncology, CHECKPOINT THERAPEUTICS, Iovance Biotherapeutics, Inc., Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-09-21 11:11:59:000
Noteworthy events during the week of September 23 - 29 for healthcare investors. More news on: Loxo Oncology, CHECKPOINT THERAPEUTICS, Iovance Biotherapeutics, Inc., Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-09-21 11:11:59:000
Noteworthy events during the week of September 23 - 29 for healthcare investors. More news on: Loxo Oncology, CHECKPOINT THERAPEUTICS, Iovance Biotherapeutics, Inc., Healthcare stocks news, , Read more … read more...
Adamis Offers A Rare Business Update
via: SeekingAlpha at 2018-08-30 20:42:09:000
We have lambasted Adamis Pharmaceuticals ( ADMP ) in multiple research notes for poor management and even poorer communication . The company only recently started accompanying its quarterly filings with press releases, though the prospect of analyst conference calls being added to the mix r… read more...
Adamis Offers A Rare Business Update
via: SeekingAlpha at 2018-08-30 20:42:09:000
We have lambasted Adamis Pharmaceuticals ( ADMP ) in multiple research notes for poor management and even poorer communication . The company only recently started accompanying its quarterly filings with press releases, though the prospect of analyst conference calls being added to the mix r… read more...
Adamis Offers A Rare Business Update
via: SeekingAlpha at 2018-08-30 20:42:09:000
We have lambasted Adamis Pharmaceuticals ( ADMP ) in multiple research notes for poor management and even poorer communication . The company only recently started accompanying its quarterly filings with press releases, though the prospect of analyst conference calls being added to the mix r… read more...
Adamis Offers A Rare Business Update
via: SeekingAlpha at 2018-08-30 20:42:09:000
We have lambasted Adamis Pharmaceuticals ( ADMP ) in multiple research notes for poor management and even poorer communication . The company only recently started accompanying its quarterly filings with press releases, though the prospect of analyst conference calls being added to the mix r… read more...
Adamis Offers A Rare Business Update
via: SeekingAlpha at 2018-08-30 20:42:09:000
We have lambasted Adamis Pharmaceuticals ( ADMP ) in multiple research notes for poor management and even poorer communication . The company only recently started accompanying its quarterly filings with press releases, though the prospect of analyst conference calls being added to the mix r… read more...
Adamis Offers A Rare Business Update
via: SeekingAlpha at 2018-08-30 20:42:09:000
We have lambasted Adamis Pharmaceuticals ( ADMP ) in multiple research notes for poor management and even poorer communication . The company only recently started accompanying its quarterly filings with press releases, though the prospect of analyst conference calls being added to the mix r… read more...
Adamis Pharma expects FDA nod for low-dose Symjepi
via: SeekingAlpha at 2018-08-27 12:34:21:000
In an update for investors, Adamis Pharmaceuticals ( ADMP -2.7% ) President & CEO Dr. Dennis Carlo says the company expects the FDA to give a thumbs up to a lower dose formulation of emergency allergy med Symjepi (epinephrine) Injection 0.15 mg. The agency's action is September 27. … read more...
Adamis Pharma expects FDA nod for low-dose Symjepi
via: SeekingAlpha at 2018-08-27 12:34:21:000
In an update for investors, Adamis Pharmaceuticals ( ADMP -2.7% ) President & CEO Dr. Dennis Carlo says the company expects the FDA to give a thumbs up to a lower dose formulation of emergency allergy med Symjepi (epinephrine) Injection 0.15 mg. The agency's action is September 27. … read more...
Adamis Pharma expects FDA nod for low-dose Symjepi
via: SeekingAlpha at 2018-08-27 12:34:21:000
In an update for investors, Adamis Pharmaceuticals ( ADMP -2.7% ) President & CEO Dr. Dennis Carlo says the company expects the FDA to give a thumbs up to a lower dose formulation of emergency allergy med Symjepi (epinephrine) Injection 0.15 mg. The agency's action is September 27. … read more...
Oversold Adamis May Rise, Lifting Spirits Of Patients And Investors Alike
via: SeekingAlpha at 2018-08-23 12:08:57:000
Source: PXHere Investors who are ready to pounce on Adamis ( ADMP ) shares at current prices may very well be rewarded handsomely in the weeks and months to come. There are multiple signs of a technical bottom and headline risk has now fully materialized with the recent approval of Teva … read more...
Oversold Adamis May Rise, Lifting Spirits Of Patients And Investors Alike
via: SeekingAlpha at 2018-08-23 12:08:57:000
Source: PXHere Investors who are ready to pounce on Adamis ( ADMP ) shares at current prices may very well be rewarded handsomely in the weeks and months to come. There are multiple signs of a technical bottom and headline risk has now fully materialized with the recent approval of Teva … read more...
Oversold Adamis May Rise, Lifting Spirits Of Patients And Investors Alike
via: SeekingAlpha at 2018-08-23 12:08:57:000
Source: PXHere Investors who are ready to pounce on Adamis ( ADMP ) shares at current prices may very well be rewarded handsomely in the weeks and months to come. There are multiple signs of a technical bottom and headline risk has now fully materialized with the recent approval of Teva … read more...
Midday Gainers / Losers (08/22/2018)
via: SeekingAlpha at 2018-08-22 12:45:18:000
Gainers: YECO +56% . NEWA +30% . EXAS +26% . MYND +22% . PSTG +17% . AGEN +14% . LZB +12% . ADMP +12% . MYGN +11% . EPE +11% . More news on: Yulong Eco-Materials, Newater Technology, Inc., EXACT Sciences Corporation, Stocks on the move, , Read more … ... read more...
Adamis Looks Cheap Despite Serious Leadership Concerns
via: SeekingAlpha at 2018-08-19 13:05:39:000
The first great victory for any developmental biotech company is to win approval for a product, especially one with a substantial market opportunity. Once approved, they face a choice: Go it alone and try to commercialize the product themselves, or find a commercial partner that will do the he… read more...
Adamis Looks Cheap Despite Serious Leadership Concerns
via: SeekingAlpha at 2018-08-19 13:05:39:000
The first great victory for any developmental biotech company is to win approval for a product, especially one with a substantial market opportunity. Once approved, they face a choice: Go it alone and try to commercialize the product themselves, or find a commercial partner that will do the he… read more...
Adamis Looks Cheap Despite Serious Leadership Concerns
via: SeekingAlpha at 2018-08-19 13:05:39:000
The first great victory for any developmental biotech company is to win approval for a product, especially one with a substantial market opportunity. Once approved, they face a choice: Go it alone and try to commercialize the product themselves, or find a commercial partner that will do the he… read more...
FDA approves Teva's generic EpiPen; shares +5.7%
via: SeekingAlpha at 2018-08-16 14:00:36:000
Teva Pharmaceutical (NYSE: TEVA ) is up 5.7% after the FDA approves its generic versions of EpiPen (and EpiPen Jr). More news on: Teva Pharmaceutical Industries Limited, Adamis Pharmaceuticals Corp., Mylan Inc, Healthcare stocks news, Stocks on the move, Top stock market news, Read m… read more...
FDA approves Teva's generic EpiPen; shares +5.7%
via: SeekingAlpha at 2018-08-16 14:00:36:000
Teva Pharmaceutical (NYSE: TEVA ) is up 5.7% after the FDA approves its generic versions of EpiPen (and EpiPen Jr). More news on: Teva Pharmaceutical Industries Limited, Adamis Pharmaceuticals Corp., Mylan Inc, Healthcare stocks news, Stocks on the move, Top stock market news, Read m… read more...
FDA approves Teva's generic EpiPen; shares +5.7%
via: SeekingAlpha at 2018-08-16 14:00:36:000
Teva Pharmaceutical (NYSE: TEVA ) is up 5.7% after the FDA approves its generic versions of EpiPen (and EpiPen Jr). More news on: Teva Pharmaceutical Industries Limited, Adamis Pharmaceuticals Corp., Mylan Inc, Healthcare stocks news, Stocks on the move, Top stock market news, Read m… read more...
Adamis Pharma Q2 revenues up 3%; shares down 2%
via: SeekingAlpha at 2018-08-10 09:31:53:000
Adamis Pharmaceuticals ( ADMP ) Q2 results ($M): Revenues: 3.9 (+2.6%); net loss: (9.7). More news on: Adamis Pharmaceuticals Corp., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more … read more...
Adamis Pharma Q2 revenues up 3%; shares down 2%
via: SeekingAlpha at 2018-08-10 09:31:53:000
Adamis Pharmaceuticals ( ADMP ) Q2 results ($M): Revenues: 3.9 (+2.6%); net loss: (9.7). More news on: Adamis Pharmaceuticals Corp., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more … read more...
Adamis Pharma Q2 revenues up 3%; shares down 2%
via: SeekingAlpha at 2018-08-10 09:31:53:000
Adamis Pharmaceuticals ( ADMP ) Q2 results ($M): Revenues: 3.9 (+2.6%); net loss: (9.7). More news on: Adamis Pharmaceuticals Corp., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more … read more...
Adamis Pharma Q2 revenues up 3%; shares down 2%
via: SeekingAlpha at 2018-08-10 09:31:53:000
Adamis Pharmaceuticals ( ADMP ) Q2 results ($M): Revenues: 3.9 (+2.6%); net loss: (9.7). More news on: Adamis Pharmaceuticals Corp., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more … read more...
Adamis Pharma Q2 revenues up 3%; shares down 2%
via: SeekingAlpha at 2018-08-10 09:31:53:000
Adamis Pharmaceuticals ( ADMP ) Q2 results ($M): Revenues: 3.9 (+2.6%); net loss: (9.7). More news on: Adamis Pharmaceuticals Corp., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more … read more...
Adamis Pharmaceuticals misses on revenue
via: SeekingAlpha at 2018-08-10 09:04:46:000
Adamis Pharmaceuticals (NASDAQ: ADMP ): Q2 Net loss of $9.7M. More news on: Adamis Pharmaceuticals Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Adamis Pharmaceuticals misses on revenue
via: SeekingAlpha at 2018-08-10 09:04:46:000
Adamis Pharmaceuticals (NASDAQ: ADMP ): Q2 Net loss of $9.7M. More news on: Adamis Pharmaceuticals Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Adamis Pharmaceuticals misses on revenue
via: SeekingAlpha at 2018-08-10 09:04:46:000
Adamis Pharmaceuticals (NASDAQ: ADMP ): Q2 Net loss of $9.7M. More news on: Adamis Pharmaceuticals Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Adamis Pharmaceuticals misses on revenue
via: SeekingAlpha at 2018-08-10 09:04:46:000
Adamis Pharmaceuticals (NASDAQ: ADMP ): Q2 Net loss of $9.7M. More news on: Adamis Pharmaceuticals Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Adamis Pharmaceuticals misses on revenue
via: SeekingAlpha at 2018-08-10 09:04:46:000
Adamis Pharmaceuticals (NASDAQ: ADMP ): Q2 Net loss of $9.7M. More news on: Adamis Pharmaceuticals Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Adamis Pharmaceuticals prices equity offering, shares down 4.5% premarket
via: SeekingAlpha at 2018-08-02 09:10:02:000
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP ) has priced its previously announced underwritten public offering of 11,666,667 common shares at $3.00 per share, for gross proceeds of ~$35M. Closing date is August 6. More news on: Adamis Pharmaceuticals Corp., Healthcare stocks news, … read more...
Adamis Pharmaceuticals prices equity offering, shares down 4.5% premarket
via: SeekingAlpha at 2018-08-02 09:10:02:000
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP ) has priced its previously announced underwritten public offering of 11,666,667 common shares at $3.00 per share, for gross proceeds of ~$35M. Closing date is August 6. More news on: Adamis Pharmaceuticals Corp., Healthcare stocks news, … read more...
Adamis Pharmaceuticals prices equity offering, shares down 4.5% premarket
via: SeekingAlpha at 2018-08-02 09:10:02:000
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP ) has priced its previously announced underwritten public offering of 11,666,667 common shares at $3.00 per share, for gross proceeds of ~$35M. Closing date is August 6. More news on: Adamis Pharmaceuticals Corp., Healthcare stocks news, … read more...
Adamis Pharmaceuticals prices equity offering, shares down 4.5% premarket
via: SeekingAlpha at 2018-08-02 09:10:02:000
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP ) has priced its previously announced underwritten public offering of 11,666,667 common shares at $3.00 per share, for gross proceeds of ~$35M. Closing date is August 6. More news on: Adamis Pharmaceuticals Corp., Healthcare stocks news, … read more...
Rounds Report: Adamis Rallied Due To A Commercialization Partnership
via: SeekingAlpha at 2018-07-05 08:52:53:000
Self-improvement comes mainly from trying to help others. - Sir John Templeton (Value Investor) Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for July 02, 2018. As usual, we'll elucidate notable trading analytics for the day, recent insider transactions, a… read more...
Rounds Report: Adamis Rallied Due To A Commercialization Partnership
via: SeekingAlpha at 2018-07-05 08:52:53:000
Self-improvement comes mainly from trying to help others. - Sir John Templeton (Value Investor) Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for July 02, 2018. As usual, we'll elucidate notable trading analytics for the day, recent insider transactions, a… read more...
Rounds Report: Adamis Rallied Due To A Commercialization Partnership
via: SeekingAlpha at 2018-07-05 08:52:53:000
Self-improvement comes mainly from trying to help others. - Sir John Templeton (Value Investor) Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for July 02, 2018. As usual, we'll elucidate notable trading analytics for the day, recent insider transactions, a… read more...
Rounds Report: Adamis Rallied Due To A Commercialization Partnership
via: SeekingAlpha at 2018-07-05 08:52:53:000
Self-improvement comes mainly from trying to help others. - Sir John Templeton (Value Investor) Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for July 02, 2018. As usual, we'll elucidate notable trading analytics for the day, recent insider transactions, a… read more...
Adamis Pharmaceuticals: The Long Wait Is Over
via: SeekingAlpha at 2018-07-04 01:51:12:000
Quotation is a serviceable substitute for wit . Oscar Wilde Adamis Pharmaceuticals ( ADMP ) has been of the most frustrating small cap biopharma stocks to hold over the past year ( Synergy Pharma ( SGYP ) being the only more maddening small cap equity). The FDA appr… read more...
What Is Adamis Worth?
via: SeekingAlpha at 2018-07-03 00:01:28:000
On the evening of July 1 st , investors in Adamis Pharmaceuticals (ADMP) received the long-awaited news that the developmental biotech had secured Novartis (NVS) as its partner to lead the US commercialization efforts for Symjepi, an FDA-approved epinephrine injector. Some of the specifics… read more...
Adamis Shares Have More Room To Run After Partnership Deal
via: SeekingAlpha at 2018-07-02 13:39:28:000
At last! After a year of negotiations, Adamis Pharmaceuticals ( ADMP ) finally announced that it had sealed the deal with a partner to commercialize its epinephrine injector, Symjepi. Sandoz, a subsidiary of Swiss drug giant Novartis ( NVS ), will be taking the lead in bringing to market t… read more...
Premarket Gainers as of 9:05 am (07/02/2018)
via: SeekingAlpha at 2018-07-02 09:19:08:000
ADMP +61% as Novartis scoops up rights to EpiPen rival. More news on: Adamis Pharmaceuticals Corp., New Concept Energy, Inc., PEDEVCO Corp., Stocks on the move, Read more … read more...
Global Stocks In The Red; EU Threatens Retaliation Over Tariffs (Wall Street Breakfast Podcast)
via: SeekingAlpha at 2018-07-02 07:24:11:000
Today's top stories: Global stocks are in the red; the EU threatens retaliation over auto tariffs; and Tesla hits target production pace. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (find all Seeking… read more...
Wall Street Breakfast: Trade Drag, Mexico's AMLO, Tesla Production
via: SeekingAlpha at 2018-07-02 06:56:31:000
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). Stocks across the globe are once again opening the week in the red as tough trade talk over the weekend weighed on … read more...
Midday Gainers / Losers (06/20/2018)
via: SeekingAlpha at 2018-06-20 12:50:22:000
Gainers: OTCPK:LFIN +40% . ADOM +38% . AETI +35% . CLBS +32% . FUV +26% . FORD +25% . DAC +24% . CLPS +24% . I +23% . LBIX +17% . More news on: LongFin Corp.A, ADOMANI, Inc., American Electric Technologies, Inc., Stocks on the move, , Read more … read more...
Midday Gainers / Losers (06/20/2018)
via: SeekingAlpha at 2018-06-20 12:50:22:000
Gainers: OTCPK:LFIN +40% . ADOM +38% . AETI +35% . CLBS +32% . FUV +26% . FORD +25% . DAC +24% . CLPS +24% . I +23% . LBIX +17% . More news on: LongFin Corp.A, ADOMANI, Inc., American Electric Technologies, Inc., Stocks on the move, , Read more … read more...
Time Is Nearly Up For Adamis
via: SeekingAlpha at 2018-06-19 10:57:39:000
We have been providing monthly updates on the seemingly endless saga of Adamis Pharmaceuticals ( ADMP ) for some time. In April, we surmised that the long-running effort to secure a commercialization partner for the FDA-approved Symjepi epinephrine injector was coming to an end . The product … read more...
INSYS' epinephrine nasal spray shows encouraging action in early-stage study; shares ahead 13%
via: SeekingAlpha at 2018-06-14 11:39:03:000
INSYS Therapeutics ( INSY +12.5% ) is up on double normal volume in apparent response to its announcement of positive data from an early-stage trial assessing its epinephrine nasal spray for the treatment of acute allergic reaction (anaphylaxis). More news on: Insys Therapeutics, Inc.,… read more...
INSYS' epinephrine nasal spray shows encouraging action in early-stage study; shares ahead 13%
via: SeekingAlpha at 2018-06-14 11:39:03:000
INSYS Therapeutics ( INSY +12.5% ) is up on double normal volume in apparent response to its announcement of positive data from an early-stage trial assessing its epinephrine nasal spray for the treatment of acute allergic reaction (anaphylaxis). More news on: Insys Therapeutics, Inc.,… read more...
INSYS' epinephrine nasal spray shows encouraging action in early-stage study; shares ahead 13%
via: SeekingAlpha at 2018-06-14 11:39:03:000
INSYS Therapeutics ( INSY +12.5% ) is up on double normal volume in apparent response to its announcement of positive data from an early-stage trial assessing its epinephrine nasal spray for the treatment of acute allergic reaction (anaphylaxis). More news on: Insys Therapeutics, Inc.,… read more...
INSYS' epinephrine nasal spray shows encouraging action in early-stage study; shares ahead 13%
via: SeekingAlpha at 2018-06-14 11:39:03:000
INSYS Therapeutics ( INSY +12.5% ) is up on double normal volume in apparent response to its announcement of positive data from an early-stage trial assessing its epinephrine nasal spray for the treatment of acute allergic reaction (anaphylaxis). More news on: Insys Therapeutics, Inc.,… read more...
Adamis Pharmaceuticals: Paging Dr. Carlo
via: SeekingAlpha at 2018-05-14 17:01:29:000
On May 10th, Adamis Pharmaceuticals ( ADMP ) delivered its latest corporate update along with its Q1 2018 earnings report . The welcome decision to include a corporate update continues a trend that began with the Q4 2017 earnings release. Previously, the company only disclosed the bare minimu… read more...
Adamis Pharmaceuticals: Paging Dr. Carlo
via: SeekingAlpha at 2018-05-14 17:01:29:000
On May 10th, Adamis Pharmaceuticals ( ADMP ) delivered its latest corporate update along with its Q1 2018 earnings report . The welcome decision to include a corporate update continues a trend that began with the Q4 2017 earnings release. Previously, the company only disclosed the bare minimu… read more...
Adamis Pharmaceuticals misses on revenue
via: SeekingAlpha at 2018-05-10 18:00:29:000
Adamis Pharmaceuticals (NASDAQ: ADMP ): Q1 Net loss of $7.6M Revenue of $3.2M (+5.3% Y/Y) misses by $0.38M . Shares -1.83% AH. Press Release More news on: Adamis Pharmaceuticals Corp., Earnings news and commentary, Healthcare stocks news, , read more...
Adamis Pharmaceuticals misses on revenue
via: SeekingAlpha at 2018-05-10 18:00:29:000
Adamis Pharmaceuticals (NASDAQ: ADMP ): Q1 Net loss of $7.6M Revenue of $3.2M (+5.3% Y/Y) misses by $0.38M . Shares -1.83% AH. Press Release More news on: Adamis Pharmaceuticals Corp., Earnings news and commentary, Healthcare stocks news, , read more...
Adamis Keeps Us Waiting: April Update
via: SeekingAlpha at 2018-04-28 06:36:40:000
We have been writing about Adamis Pharmaceuticals ( ADMP ) for several months. We have opined on the value of its FDA-approved epinephrine injector, Symjepi, as well as that of its budding pipeline. We have also discussed at length the agonizingly long process the company has undertaken to fin… read more...
Adamis Keeps Us Waiting: April Update
via: SeekingAlpha at 2018-04-28 06:36:40:000
We have been writing about Adamis Pharmaceuticals ( ADMP ) for several months. We have opined on the value of its FDA-approved epinephrine injector, Symjepi, as well as that of its budding pipeline. We have also discussed at length the agonizingly long process the company has undertaken to fin… read more...
Adamis: Wait For It
via: SeekingAlpha at 2018-04-04 12:00:30:000
Adamis Pharmaceuticals (ADMP) is burning cash fast, and they will continue to burn cash until they find a partner for Symjepi. Cash and dilution are now real concerns as there is not a timetable for a partnership deal. Time is not on ADMPs side. The longer it takes to find a partner, t… read more...
Adamis: Wait For It
via: SeekingAlpha at 2018-04-04 12:00:30:000
Adamis Pharmaceuticals (ADMP) is burning cash fast, and they will continue to burn cash until they find a partner for Symjepi. Cash and dilution are now real concerns as there is not a timetable for a partnership deal. Time is not on ADMPs side. The longer it takes to find a partner, t… read more...
Understanding Binary Catalysts: A Brief Guide For Biotech Investors
via: SeekingAlpha at 2018-03-29 02:38:12:000
This article was co-authored by Stepan Lavrouk. Stepan is an investment analyst with Almington Capital. We have written extensively on Seeking Alpha about a range of biotech stocks. But we have also spent some time addressing the activity of biotech investing itself. In previous articles… read more...
Understanding Binary Catalysts: A Brief Guide For Biotech Investors
via: SeekingAlpha at 2018-03-29 02:38:12:000
This article was co-authored by Stepan Lavrouk. Stepan is an investment analyst with Almington Capital. We have written extensively on Seeking Alpha about a range of biotech stocks. But we have also spent some time addressing the activity of biotech investing itself. In previous articles… read more...
Adamis Pharmaceuticals: The Latest Update Still Keeps Us Waiting
via: SeekingAlpha at 2018-03-21 15:31:55:000
Investors in Adamis Pharmaceuticals ( ADMP ) are no strangers to long silences. Company management, under the leadership of CEO Dennis Carlo, has long made a habit of keeping mum about developments. This has been especially galling in recent months, as Adamis blew past its initial plans to sec… read more...
Adamis Pharmaceuticals: The Latest Update Still Keeps Us Waiting
via: SeekingAlpha at 2018-03-21 15:31:55:000
Investors in Adamis Pharmaceuticals ( ADMP ) are no strangers to long silences. Company management, under the leadership of CEO Dennis Carlo, has long made a habit of keeping mum about developments. This has been especially galling in recent months, as Adamis blew past its initial plans to sec… read more...
Your Daily Pharma Scoop: Aratana Earnings, Vanda Offering, Opko 4kscore Shows Benefit
via: SeekingAlpha at 2018-03-17 08:00:00:000
Quick investment opinion: Aratana Therapeutics Aratana (NASDAQ: PETX ), which we covered in the early days of our Seeking Alpha work, released earnings this week. In our July 2017 article, we had said that although PETX is having trouble delivering drugs even after approval, its strong pip… read more...
Your Daily Pharma Scoop: Aratana Earnings, Vanda Offering, Opko 4kscore Shows Benefit
via: SeekingAlpha at 2018-03-17 08:00:00:000
Quick investment opinion: Aratana Therapeutics Aratana (NASDAQ: PETX ), which we covered in the early days of our Seeking Alpha work, released earnings this week. In our July 2017 article, we had said that although PETX is having trouble delivering drugs even after approval, its strong pip… read more...
Adamis Pharmaceuticals misses by $0.09, misses on revenue
via: SeekingAlpha at 2018-03-16 10:06:34:000
Adamis Pharmaceuticals (NASDAQ: ADMP ): FY EPS of -$0.90 misses by $0.09 . Revenue of $13.07M (+102.0% Y/Y) misses by $1.33M . Press Release More news on: Adamis Pharmaceuticals Corp., Earnings news and commentary, Healthcare stocks news, , read more...
Adamis Pharmaceuticals misses by $0.09, misses on revenue
via: SeekingAlpha at 2018-03-16 10:06:34:000
Adamis Pharmaceuticals (NASDAQ: ADMP ): FY EPS of -$0.90 misses by $0.09 . Revenue of $13.07M (+102.0% Y/Y) misses by $1.33M . Press Release More news on: Adamis Pharmaceuticals Corp., Earnings news and commentary, Healthcare stocks news, , read more...
Adamis on go to start late-stage studies of APC-1000 in asthma
via: SeekingAlpha at 2018-03-16 09:08:59:000
Adamis Pharmaceuticals (NASDAQ: ADMP ) announces that the FDA has signed off on Phase 3 clinical trials assessing APC-1000 in asthma patients. The studies should launch later this year. More news on: Adamis Pharmaceuticals Corp., Healthcare stocks news, Read more … read more...
Adamis on go to start late-stage studies of APC-1000 in asthma
via: SeekingAlpha at 2018-03-16 09:08:59:000
Adamis Pharmaceuticals (NASDAQ: ADMP ) announces that the FDA has signed off on Phase 3 clinical trials assessing APC-1000 in asthma patients. The studies should launch later this year. More news on: Adamis Pharmaceuticals Corp., Healthcare stocks news, Read more … read more...
Adamis Shows Off Symjepi's Value. Now It Needs To Close The Deal
via: SeekingAlpha at 2018-03-08 18:17:57:000
Shares of Adamis Pharmaceuticals ( ADMP ) took a precipitous plunge in late February as investors' fears that partnership discussions for the commercialization of Symjepi, the company's FDA-approved epinephrine injector, had stalled - or even fallen apart completely. A timely update on Feb… read more...
Adamis Shows Off Symjepi's Value. Now It Needs To Close The Deal
via: SeekingAlpha at 2018-03-08 18:17:57:000
Shares of Adamis Pharmaceuticals ( ADMP ) took a precipitous plunge in late February as investors' fears that partnership discussions for the commercialization of Symjepi, the company's FDA-approved epinephrine injector, had stalled - or even fallen apart completely. A timely update on Feb… read more...
Adamis Pharmaceuticals: January Thesis Update
via: SeekingAlpha at 2018-01-25 04:30:36:000
Disappointment in Adamis Pharmaceuticals ( ADMP ) and its management has continued to mount as silence concerning negotiations with potential licensing partners for Symjepi, its FDA-approved epinephrine injector, remains deafening. The only available updates are repetitions of what has been sa… read more...
Adamis Pharmaceuticals: January Thesis Update
via: SeekingAlpha at 2018-01-25 04:30:36:000
Disappointment in Adamis Pharmaceuticals ( ADMP ) and its management has continued to mount as silence concerning negotiations with potential licensing partners for Symjepi, its FDA-approved epinephrine injector, remains deafening. The only available updates are repetitions of what has been sa… read more...
Watch These December Biotech Catalysts: A Retrospective
via: SeekingAlpha at 2018-01-04 05:09:30:000
Early last month I wrote an article about a group of biotech stocks with catalysts expected during the last days of 2017. Adamis Pharmaceuticals ( ADMP ), Progenics Pharmaceuticals ( PGNX ), and Novavax ( NVAX ) all had major catalysts scheduled or expected. Some delivered, while others did … read more...
2 Small Biopharma CEOs That Should Be Sacked
via: SeekingAlpha at 2017-12-22 12:32:18:000
Marriage must fight constantly against a monster which devours everything: routine . Honor de Balzac The beaten down shares of Synergy Pharmaceuticals ( SGYP ) have now moved up some 15% in trading since their CEO resigned on Tuesday. We posted an article around… read more...
Biotech Options Traders Are Playing With Fire
via: SeekingAlpha at 2017-12-15 10:04:37:000
The one advantage of playing with fire is that one never gets even singed. It is the people who don't know how to play with it who get burned up. Oscar Wilde Peter Lynch, perhaps the greatest mutual fund manager of all time, has warned about the dangers of options for years… read more...
Can Adamis Bleed Mylan Dry?
via: SeekingAlpha at 2017-12-13 13:44:20:000
Investors and followers of Adamis Pharmaceuticals ( ADMP ) have been desperate for news of a commercial partnership for Symjepi, the company's new competitor to Mylan's ( MYL ) EpiPen. I have been writing about the stock for a while now , and on December 12th I had a fairly lengthy discussion… read more...
Your Daily Pharma Scoop: Gilead's Potential, Celgene CAR-T Candidate, Cellectar Soars
via: SeekingAlpha at 2017-12-07 08:00:00:000
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day ea… read more...
Midday Gainers / Losers
via: SeekingAlpha at 2017-12-05 12:41:26:000
Gainers: CUR +101% . RVNC +35% . CLIR +28% . BNED +19% . GLBS +15% . ADMP +13% . GRAM +15% . MBRX +14% . GIII +13% . NES +13% . More news on: Neuralstem, Inc., Revance Therapeutics, Inc., ClearSign Combustion Corp., Stocks on the move, Read more … read more...
Watch These December Biotech Catalysts
via: SeekingAlpha at 2017-12-05 11:07:46:000
December is a month meant to be filled with goodwill, cheer, family harmony, and indulgence in food and drink. Of course, many a Christmas season is also filled with anxiety, enmity, anger, and recrimination. For investors in a few of the most interesting biotech stocks will probably be feelin… read more...
Premarket Gainers as of 9:05 am
via: SeekingAlpha at 2017-11-30 09:12:00:000
SHLD +26% on Q3 earning . More news on: Sears Holdings Corporation, New York & Company, Inc., Adamis Pharmaceuticals Corp., Stocks on the move, Read more … read more...
Your Daily Pharma Scoop: Valeant's B+L In India, TXMD's NDA Resubmission, Melinta Makes An Acquisition
via: SeekingAlpha at 2017-11-30 08:28:28:000
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Valeant B+L This is a tidy little art… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|---|---|---|---|---|---|
| 2013-12-13 | 17.0 | 1.0 | 17.0 |